Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

In vitro Biological Characterization of IFN-β-1a major Glycoforms.
Immune reconstitution inflammatory syndrome in a patient treated with natalizumab presenting progressive multifocal leukoencephalopathy.
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
On dihydroorotate dehydrogenases, their inhibitors and uses.
Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis.
Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult.
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past.
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
ATX-MS-1467 - Positive Immunological data in Multiple Sclerosis: Final Phase I/IIa data shows safety and tolerability, plus efficacy
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.
MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis.
Response to "Glucocorticoids for treating Takotsubo syndrome?" and "Atypical global Takotsubo syndrome in a patient with acute disseminated encephalomyelitis".
Connective Tissue and its Growth Factor, CTGF, Distinguish the Morphometric and Molecular Remodeling of the Bladder in a Model of Neurogenic Bladder.
Absence of mannose-binding lectin in a female with relapsing-remitting multiple sclerosis.
Celiac disease and multiple sclerosis in the northwest of Iran.
The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry.
Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease.
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.
Ocrelizumab in multiple sclerosis: risks and benefits.
Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
Severe haematological complications during treatment with natalizumab.

Pages